Transient increase of interferon-stimulated genes and no clinical benefit by chloroquine treatment during acute simian immunodeficiency virus infection of macaques

AIDS Research and Human Retroviruses

Volumn 30, Issue 4, 2014, Pages 355-362

  Vaccari, Monica ^a   Fenizia, Claudio ^a   Ma, Zhong Min ^b   Hryniewicz, Anna ^a   Boasso, Adriano ^a,f   Doster, Melvin N ^a   Miller, Christopher J ^b   Lindegardh, Niklas ^c,d,g   Tarning, Joel ^c,d   Landay, Alan L ^e   Shearer, Gene M ^a   Franchini, Genoveffa ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e RUSH UNIVERSITY MEDICAL CENTER   (United States)

^f MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^g CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CHLOROQUINE; INTERFERON;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD4+ T LYMPHOCYTE; CONTROLLED STUDY; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOREACTIVITY; INTERFERON PRODUCTION; MACACA; NONHUMAN; PRIORITY JOURNAL; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN VIRUS;

ANIMALS; CHLOROQUINE; IMMUNOLOGIC FACTORS; MACACA MULATTA; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TREATMENT OUTCOME;

EID: 84898752676     PISSN: 08892229     EISSN: 19318405     Source Type: Journal    
DOI: 10.1089/aid.2013.0218     Document Type: Article

References (52)

1. Valdez H and Lederman MM: Cytokines and cytokine therapies in HIV infection. AIDS Clin Rev 1997;1997-1998: 187-228.
2. Connolly NC, Riddler SA, and Rinaldo CR: Proinflammatory cytokines in HIV disease-A review and rationale for new therapeutic approaches. AIDS Rev 2005;7(3):168-180. (Pubitemid 41671917)
3. Boasso A and Shearer GM: Chronic innate immune activation as a cause of HIV-1 immunopathogenesis. Clin Immunol 2008;126(3):235-242. (Pubitemid 351221427)
4. Ascher MS, Sheppard HW, Krowka JF, and Bremermann HJ: AIDS as immune system activation. Key questions that remain. Adv Exp Med Biol 1995;374:203-210.
5. Sodora DL and Silvestri G: Immune activation and AIDS pathogenesis. AIDS 2008;22(4):439-446. (Pubitemid 351317285)
6. Douek D: HIV disease progression: Immune activation, microbes, and a leaky gut. Top HIV Med 2007;15(4):114-117.
7. Herbeuval JP, Nilsson J, Boasso A, et al.: Differential expression of IFN-Alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc Natl Acad Sci USA 2006;103(18):7000-7005.
8. Accornero P, Radrizzani M, Delia D, et al.: Differential susceptibility to HIV-GP120-sensitized apoptosis in CD4+ T-cell clones with different T-helper phenotypes: Role of CD95/CD95L interactions. Blood 1997;89(2):558-569. (Pubitemid 27051692)
9. Boasso A, Hardy AW, Anderson SA, Dolan MJ, and Shearer GM: HIV-induced type I interferon and tryptophan catabolism drive T cell dysfunction despite phenotypic activation. PLoS One 2008;3(8):e2961.
10. Herbeuval JP and Shearer GM: HIV-1 immunopathogenesis: How good interferon turns bad. Clin Immunol 2007;123(2): 121-128. (Pubitemid 46590066)
11. Boasso A, Vaccari M, Fuchs D, et al.: Combined effect of antiretroviral therapy and blockade of IDO in SIV-infected rhesus macaques. J Immunol 2009;182(7):4313-4320.
12. Pitha PM: Multiple effects of interferon on the replication of human immunodeficiency virus type 1. Antiviral Res 1994; 24(2-3):205-219. (Pubitemid 24228875)
13. Fox NW and McArthur CP: Acquired immunodeficiency syndrome-A review and update. History, characteristics of human immunodeficiency virus infection, its replication, biologic factors, and pathogenicity. Arch Fam Med 1993; 2(10):1068-1077.
14. Wallace DJ: The use of chloroquine and hydroxychloroquine for non-infectious conditions other than rheumatoid arthritis or lupus: A critical review. Lupus 1996;5(Suppl 1):S59-S64. (Pubitemid 26196744)
15. Klinger G, Morad Y, Westall CA, et al.: Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. Lancet 2001;358(9284):813-814. (Pubitemid 32868737)
16. Tsai WP, Nara PL, Kung HF, and Oroszlan S: Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses 1990;6(4):481-489.
17. Sperber K, Kalb TH, Stecher VJ, Banerjee R, and Mayer L: Inhibition of human immunodeficiency virus type 1 replication by hydroxychloroquine in T cells and monocytes. AIDS Res Hum Retroviruses 1993;9(1):91-98. (Pubitemid 23055136)
18. Savarino A, Lucia MB, Rastrelli E, et al.: Anti-HIV effects of chloroquine: Inhibition of viral particle glycosylation and synergism with protease inhibitors. J Acquir Immune Defic Syndr 2004;35(3):223-232. (Pubitemid 38280647)
19. Beignon AS, McKenna K, Skoberne M, et al.: Endocytosis of HIV-1 activates plasmacytoid dendritic cells via Toll-like receptor-viral RNA interactions. J Clin Invest 2005;115(11): 3265-3275. (Pubitemid 41567591)
20. Schmidt B, Ashlock BM, Foster H, Fujimura SH, and Levy JA: HIV-infected cells are major inducers of plasmacytoid dendritic cell interferon production, maturation, and migration. Virology 2005;343(2):256-266. (Pubitemid 41598365)
21. Hardy AW, Graham DR, Shearer GM, and Herbeuval JP: HIV turns plasmacytoid dendritic cells (pDC) into TRAILexpressing killer pDC and down-regulates HIV coreceptors by Toll-like receptor 7-induced IFN-Alpha. Proc Natl Acad Sci USA 2007;104(44):17453-17458. (Pubitemid 350219859)
22. Ma M, Wang L, Yang J, et al.: Age-related impaired Th1 responses to PRV vaccine in vivo in aged pigs. Mol Immunol 2012;52(3-4):217-223.
23. Rutz M, Metzger J, Gellert T, et al.: Toll-like receptor 9 binds single-stranded CpG-DNA in a sequence-And pH-dependent manner. Eur J Immunol 2004;34(9):2541-2550. (Pubitemid 39302811)
24. Piconi S, Parisotto S, Rizzardini G, et al.: Hydroxychloroquine drastically reduces immune activation in HIV-infected, antiretroviral therapy-treated immunologic nonresponders. Blood 2011;118(12):3263-3272.
25. Murray SM, Down CM, Boulware DR, et al.: Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol 2010;84(22):12082-12086.
26. Paton NI, Goodall RL, Dunn DT, et al.: Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: A randomized controlled trial. JAMA 2012; 308(4):353-361.
27. Liovat AS, Jacquelin B, Ploquin MJ, Barre-Sinoussi F, and Muller-Trutwin MC: African non human primates infected by SIV-why don't they get sick Lessons from studies on the early phase of non-pathogenic SIV infection. Curr HIV Res 2009;7(1):39-50.
28. Paiardini M, Pandrea I, Apetrei C, and Silvestri G: Lessons learned from the natural hosts of HIV-related viruses. Annu Rev Med 2009;60:485-495.
29. Mandl JN, Barry AP, Vanderford TH, et al.: Divergent TLR7 and TLR9 signaling and type I interferon production distinguish pathogenic and nonpathogenic AIDS virus infections. Nat Med 2008;14(10):1077-1087.
30. Jacquelin B, Mayau V, Targat B, et al.: Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 2009; 119(12):3544-3555.
31. Bosinger SE, Li Q, Gordon SN, et al.: Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys. J Clin Invest 2009;119(12): 3556-3572.
32. Blessborn D, Neamin G, Bergqvist Y, and Lindegardh N: A new approach to evaluate stability of amodiaquine and its metabolite in blood and plasma. J Pharm Biomed Anal 2006;41(1):207-212.
33. Romano JW, Shurtliff RN, Dobratz E, et al.: Quantitative evaluation of simian immunodeficiency virus infection using NASBA technology. J Virol Methods 2000;86(1):61-70. (Pubitemid 30136204)
34. Vaccari M, Boasso A, Ma ZM, et al.: CD4 + T-cell loss and delayed expression of modulators of immune responses at mucosal sites of vaccinated macaques following SIV(mac251) infection. Mucosal Immunol 2008;1(6):497-507.
35. Vaccari M, Trindade CJ, Venzon D, Zanetti M, and Franchini G: Vaccine-Induced CD8+ central memory T cells in protection from simian AIDS. J Immunol 2005;175(6): 3502-3507. (Pubitemid 41292007)
36. Boasso A, Herbeuval JP, Hardy AW, Winkler C, and Shearer GM: Regulation of indoleamine 2,3-dioxygenase and tryptophanyl-tRNA-synthetase by CTLA-4-Fc in human CD4+ T cells. Blood 2005;105(4):1574-1581. (Pubitemid 40223677)
37. Hughes R, Towers G, and Noursadeghi M: Innate immune interferon responses to human immunodeficiency virus-1 infection. Rev Med Virol 2012;22(4):257-266.
38. Miller DR, Khalil SK, and Nygard GA: Steady-state pharmacokinetics of hydroxychloroquine in rheumatoid arthritis patients. DICP 1991;25(12):1302-1305.
39. Rosenthal AR, Kolb H, Bergsma D, Huxsoll D, and Hopkins JL: Chloroquine retinopathy in the rhesus monkey. Invest Ophthalmol Vis Sci 1978;17(12):1158- 1175. (Pubitemid 9030521)
40. Samuel CE: Antiviral actions of interferons. Clin Microbiol Rev 2001;14(4):778-809, table. (Pubitemid 32979631)
41. Naarding MA, Baan E, Pollakis G, and Paxton WA: Effect of chloroquine on reducing HIV-1 replication in vitro and the DC-SIGNmediated transfer of virus to CD4 + T-lymphocytes. Retrovirology 2007;4:6.
42. Silvestri G, Sodora DL, Koup RA, et al.: Nonpathogenic SIV infection of sooty mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003;18(3):441-452. (Pubitemid 36351522)
43. Brenchley JM, Price DA, Schacker TW, et al.: Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med 2006;12(12):1365-1371. (Pubitemid 44924494)
44. Funderburg N, Luciano AA, Jiang W, et al.: Toll-like receptor ligands induce human T cell activation and death, a model for HIV pathogenesis. PLoS One 2008;3(4):e1915.
45. Benveniste O, Flahault A, Rollot F, et al.: Mechanisms involved in the low-level regeneration of CD4 + cells in HIV-1-infected patients receiving highly active antiretroviral therapy who have prolonged undetectable plasma viral loads. J Infect Dis 2005;191(10):1670-1679. (Pubitemid 40656755)
46. Fox RI: Mechanism of action of hydroxychloroquine as an antirheumatic drug. Semin Arthritis Rheum 1993;23(2 Suppl 1):82-91.
47. Wallace DJ: Antimalarial agents and lupus. Rheum Dis Clin North Am 1994;20(1):243-263. (Pubitemid 24066019)
48. Macfarlane DE and Manzel L: Antagonism of immunostimulatory CpG-oligodeoxynucleotides by quinacrine, chloroquine, and structurally related compounds. J Immunol 1998;160(3):1122-1131. (Pubitemid 28093406)
49. Manzel L, Strekowski L, Ismail FM, Smith JC, and Macfarlane DE: Antagonism of immunostimulatory CpGoligodeoxynucleotides by 4-Aminoquinolines and other weak bases: Mechanistic studies. J Pharmacol Exp Ther 1999; 291(3):1337-1347.
50. Weber F, Kochs G, and Haller O: Inverse interference: How viruses fight the interferon system. Viral Immunol 2004; 17(4):498-515. (Pubitemid 40054230)
51. Hong Z, Jiang Z, Liangxi W, et al.: Chloroquine protects mice from challenge with CpG ODN and LPS by decreasing proinflammatory cytokine release. Int Immunopharmacol 2004;4(2):223-234. (Pubitemid 38296351)
52. Martinson JA, Montoya CJ, Usuga X, et al.: Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: Implication for T-cell activation. Antimicrob Agents Chemother 2010;54(2):871-881.